PharmaShots | Incisive News in 3 Shots

Subscribe Now

Nasopharyngeal Carcinoma

Junshi and Coherus Report the US FDA Acceptance of BLA for Toripalimab to Treat Nasopharyngeal Carcinoma

Junshi and Coherus Report the US FDA Acceptance of BLA for Toripalimab to Treat Nasopharyngeal Carcinoma

November 2, 2021

Junshi and Coherus's Toripalimab Receive the US FDA's Breakthrough Therapy Designation as 1L Treatment of Nasopharyngeal Carcinoma

Junshi and Coherus's Toripalimab Receive the US FDA's Breakthrough Therapy Designation as 1L Treatment of Nasopharyngeal Carcinoma

August 13, 2021

Junshi Reports Results of Dual Regimen in P-III Jupiter-02 Study as 1L Therapy for Nasopharyngeal Carcinoma

Junshi Reports Results of Dual Regimen in P-III Jupiter-02 Study as 1L Therapy for Nasopharyngeal Carcinoma

September 30, 2020

Junshi's Toripalimab Receives the US FDA's Breakthrough Therapy Designation for the Treatment of Nasopharyngeal Carcinoma

Junshi's Toripalimab Receives the US FDA's Breakthrough Therapy Designation for the Treatment of Nasopharyngeal Carcinoma

September 10, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us